Literature DB >> 2826951

Morphine-6-glucuronide, a potent mu agonist.

G W Pasternak1, R J Bodnar, J A Clark, C E Inturrisi.   

Abstract

The 3- and the 6-glucuronides of morphine have been examined in binding studies and in vivo. The 3-glucuronide had poor affinity in all binding studies whereas the 6-glucuronide potently labeled mu, but not delta or kappa receptors with affinities similar to morphine. Microinjections of the 3-glucuronide directly into the periaqueductal gray were without effect. The 6-glucuronide, on the other hand, was up to 20-fold more potent than morphine following microinjections in the same region. High doses of the 6-glucuronide produced profound seizure activity. All 6-glucuronide actions were sensitive to the opiate antagonist naloxone.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2826951     DOI: 10.1016/0024-3205(87)90431-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  60 in total

1.  Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.

Authors:  M R Bouw; R Xie; K Tunblad; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

2.  Morphine-6 beta-glucuronide has a higher efficacy than morphine as a mu-opioid receptor agonist in the rat locus coeruleus.

Authors:  P B Osborne; B Chieng; M J Christie
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  Sex hormones differentially regulate isoforms of UDP-glucuronosyltransferase.

Authors:  S I Strasser; S A Smid; M L Mashford; P V Desmond
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

4.  A computer-based system for controlling plasma opioid concentration according to patient need for analgesia.

Authors:  H F Hill; R C Jacobson; B A Coda; A M Mackie
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 5.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations.

Authors:  J Hasselström; N Alexander; C Bringel; J O Svensson; J Säwe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 7.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

8.  Heroin intoxication: the relation between plasma morphine concentration and clinical state at admission.

Authors:  J Gutierrez-Cebollada; J Camí; R de la Torre
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Affinity profiles of novel delta-receptor selective benzofuran derivatives of non-peptide opioids.

Authors:  M Spetea; S T Nevin; S Hosztafi; A Z Rónai; G Tóth; A Borsodi
Journal:  Neurochem Res       Date:  1998-09       Impact factor: 3.996

10.  Placental transfer and fetal elimination of morphine-3-beta-glucuronide in the pregnant baboon.

Authors:  Marianne Garland; Kirsten M Abildskov; Tung-Wah Kiu; Salha S Daniel; Piper Weldy; Raymond I Stark
Journal:  Drug Metab Dispos       Date:  2008-06-19       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.